Acetyl-coenzyme A carboxylase inhibition reduces de novo lipogenesis in overweight male subjects: A randomized, double-blind, crossover study

Hepatology

Volumn 66, Issue 2, 2017, Pages 324-334

  Stiede, Kathryn ^a   Miao, Wenyan ^a   Blanchette, Heather S ^a   Beysen, Carine ^b   Harriman, Geraldine ^a   Harwood, H James ^a   Kelley, Heather ^a   Kapeller, Rosana ^a   Schmalbach, Tess ^a   Westlin, William F ^a  

^a Nimbus Therapeutics   (United States)

^b KINEMED INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ACETYL COENZYME A CARBOXYLASE INHIBITOR; BIOLOGICAL MARKER; FRUCTOSE; ORGANIC ANION TRANSPORTER; PALMITIC ACID; STABLE ISOTOPE; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; ENZYME INHIBITION; FEMALE; FLATULENCE; HUMAN; LIPOGENESIS; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; MALE; NONALCOHOLIC FATTY LIVER; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TREATMENT DURATION; ANTAGONISTS AND INHIBITORS; BODY MASS; COMPARATIVE STUDY; DRUG ADMINISTRATION; FOLLOW UP; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; OVERWEIGHT; PATIENT SAFETY; PHYSIOLOGY; RISK ASSESSMENT; TREATMENT OUTCOME;

ACETYL-COA CARBOXYLASE; ADMINISTRATION, ORAL; ADULT; BODY MASS INDEX; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HUMANS; LIPOGENESIS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; OVERWEIGHT; PATIENT SAFETY; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 85021827837     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.29246     Document Type: Article

References (28)

1. Dyson JK, Anstee QM, McPherson S. Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. Frontline Gastroenterol 2014;5:211-218.
2. Harwood HJ Jr. Treating the metabolic syndrome: acetyl-CoA carboxylase inhibition. Expert Opin Ther Targets 2005;9:267-281.
3. Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 2010;52:774-788.
4. Tong L, Harwood HJ Jr. Acetyl-CoA carboxylases: versatile targets for drug discovery. J Cell Biochem 2006;99:1476-1488.
5. Kim KH. Regulation of mammalian acetyl-coenzyme A carboxylase. Annu Rev Nutr 1997;17:77-99.
6. Harriman G, Greenwood J, Bhat S, Huang X, Wang R, Paul D, et al. Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats. Proc Natl Acad Sci USA 2016;113:E1796-E1805.
7. Fullerton MD, Galic S, Marcinko K, Sikkema S, Pulinikunnil T, Chen ZP, et al. Single phosphorylation sites in ACC1 and ACC2 regulate lipid homeostasis and the lipid-sensitizing effects of metformin. Nat Med 2013;19:1649-1654.
8. Hellerstein MK, Neese RA. Mass isotopomer distribution analysis: a technique for measuring biosynthesis and turnover of polymers. Am J Physiol 1992;263:E988-E1001.
9. Westlin WF, Harriman G, Harwood HJ, Kapeller R, Lennon S, Miao W, et al. NDI-010976, a potent, liver-directed, oral inhibitor of acetyl-CoA carboxylase for non-alcoholic steatohepatitis: a phase 1 single ascending dose study in healthy volunteers [Abstract]. J Hepatol 2016;2(Suppl.):S501-S502.
10. Hellerstein MK. De novo lipogenesis in humans: metabolic and regulatory aspects. Eur J Clin Nutr 1999;53:S53-S65.
11. Beysen C, Murphy EJ, Nagaraja H, Decaris M, Riiff T, Fong A, et al. A pilot study of the effects of pioglitazone and rosiglitazone on de novo lipogenesis in type 2 diabetes. J Lipid Res 2008;49:2657-2663.
12. Shen H, Yang Z, Mintier G, Han Y-H, Chen C, Balimane P, et al. Cynomolgus monkey as a potential model to assess drug interactions involving hepatic organic anion transporting polypeptides: in vitro, in vivo, and in vitro-to-in vivo extrapolation. J Pharmacol Exp Ther 2013;344:673-685.
13. Bleasby K, Castle JC, Roberts CJ, Cheng C, Bailey WJ, Sina JF, et al. Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition. Xenobiotica 2006;36:963-988.
14. Evers R, Chu X-Y. Role of the murine organic anion-transporting polypeptide 1b2 (Oatp1b2) in drug disposition and hepatotoxicity. Mol Pharmacol 2008;74:309-311.
15. McGarry JD. Banting lecture 2001. Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002;51:7-18.
16. Topping DL, Mayes PA. The immediate effects of insulin and fructose on the metabolism of the perfused liver. Changes in lipoprotein secretion, fatty acid oxidation and esterification, lipogenesis and carbohydrate metabolism. Biochem J 1972;126:295-311.
17. Listenberger LL, Han X, Lewis SE, Cases S, Farese RV Jr, Ory DS, et al. Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc Natl Acad Sci USA 2003;100:3077-3082.
18. Wang D, Wei Y, Pagliassotti MJ. Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cells. Am J Physiol Endocrinol Metab 2006;291:E275-E281.
19. Jump DB, Torres-Gonzalez M, Olson LK. Soraphen A, an inhibitor of acetyl CoA carboxylase activity, interferes with fatty acid elongation. Biochem Pharmacol 2011;81:649-660.
20. Fabbrini E, Mohammed BS, Magkos F, Korenblat KM, Patterson BW, Klein S. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology 2008;134:424-431.
21. Sevastianova K, Santos A, Kotronen A, Hakkarainen A, Makkonen J, Silander K, et al. Effect of short-term carbohydrate overfeeding and long-term weight loss on liver fat in overweight humans. Am J Clin Nutr 2012;96:727-734.
22. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005;115:1343-1351.
23. Lambert JE, Ramos-Roman MA, Browning JD, Parks EJ. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology 2014;146:726-735.
24. Wilke MS, French MA, Goh YK, Ryan EA, Jones PJ, Clandinin MT. Synthesis of specific fatty acids contributes to VLDL-triacylglycerol composition in humans with and without type 2 diabetes. Diabetologia 2009;52:1628-1637.
25. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, vitamin E or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010;362:1675-1685.
26. Vedala A, Wang W, Neese RA, Christiansen MP, Hellerstein MK. Delayed secretory pathway contributions to VLDL-triglycerides from plasma NEFA, diet, and de novo lipogenesis in humans. J Lipid Res 2006;47:2562-2574.
27. Harwood HJ Jr, Petras SF, Shelly LD, Zaccaro LM, Perry DA, Makowski MR, et al. Isozyme-nonselective N-substituted bipiperidylcarboxamide acetyl-CoA carboxylase inhibitors reduce tissue malonyl-CoA concentrations, inhibit fatty acid synthesis, and increase fatty acid oxidation in cultured cells and in experimental animals. J Biol Chem 2003;278:37099-37111.
28. Griffith DA, Kung DW, Esler WP, Amor PA, Bagley SW, Beysen C, et al. Decreasing the rate of metabolic ketone reduction in the discovery of a clinical acetyl-CoA carboxylase inhibitor for the treatment of diabetes. J Med Chem 2014;57:10512-10526.